header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-FISH-160913-2
Fish name: s843Tg; um13Tg + MO1-sox18
Genotype: s843Tg; um13Tg
Targeting Reagent: MO1-sox18
HUMAN DISEASE MODELED by s843Tg; um13Tg + MO1-sox18
No data available
GENE EXPRESSION
Gene expression in s843Tg; um13Tg + MO1-sox18
RNA expression No data available
Protein expression No data available
PHENOTYPE
Phenotype in s843Tg; um13Tg + MO1-sox18
Phenotype Conditions Figures
blood vessel development process quality, normal control Fig. 6 from Duong et al., 2014
dorsal aorta fused with posterior cardinal vein, abnormal chemical treatment by environment: semaxanib Fig. 6 from Duong et al., 2014
dorsal aorta fused with posterior cardinal vein, abnormal chemical treatment by environment: U0126 Fig. 6 from Duong et al., 2014
dorsal aorta fused with posterior cardinal vein, abnormal chemical treatment by environment: 2-(2-amino-3-methoxyphenyl)chromen-4-one Fig. 6 from Duong et al., 2014
dorsal aorta separated from posterior cardinal vein, normal standard conditions Fig. 1Fig. 6 from Duong et al., 2014
dorsal aorta blood vessel development process quality, abnormal chemical treatment by environment: 2-(2-amino-3-methoxyphenyl)chromen-4-one Fig. 6 from Duong et al., 2014
dorsal aorta blood vessel development process quality, abnormal chemical treatment by environment: semaxanib Fig. 6 from Duong et al., 2014
dorsal aorta blood vessel development process quality, abnormal chemical treatment by environment: U0126 Fig. 6 from Duong et al., 2014
dorsal aorta blood vessel development process quality, normal standard conditions Fig. 1Fig. 6 from Duong et al., 2014
dorsal aorta blood vessel endothelium EGFP expression decreased amount, abnormal standard conditions Fig. 5 from Duong et al., 2014
posterior cardinal vein blood vessel development process quality, abnormal chemical treatment by environment: U0126 Fig. 6 from Duong et al., 2014
posterior cardinal vein blood vessel development process quality, abnormal chemical treatment by environment: semaxanib Fig. 6 from Duong et al., 2014
posterior cardinal vein blood vessel development process quality, abnormal chemical treatment by environment: 2-(2-amino-3-methoxyphenyl)chromen-4-one Fig. 6 from Duong et al., 2014
posterior cardinal vein blood vessel development process quality, normal standard conditions Fig. 1Fig. 6 from Duong et al., 2014
posterior cardinal vein blood vessel endothelium EGFP expression decreased amount, abnormal standard conditions Fig. 5 from Duong et al., 2014

CITATIONS  (1)